BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 21654317)

  • 1. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
    Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
    Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.
    Li Y; Guessous F; DiPierro C; Zhang Y; Mudrick T; Fuller L; Johnson E; Marcinkiewicz L; Engelhardt M; Kefas B; Schiff D; Kim J; Abounader R
    Mol Cancer Ther; 2009 Feb; 8(2):376-85. PubMed ID: 19190120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
    Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
    Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
    Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
    BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.
    Davis IJ; McFadden AW; Zhang Y; Coxon A; Burgess TL; Wagner AJ; Fisher DE
    Cancer Res; 2010 Jan; 70(2):639-45. PubMed ID: 20068147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
    Meng L; Shu M; Chen Y; Yang D; He Q; Zhao H; Feng Z; Liang C; Yu K
    Cancer Biol Ther; 2014 Jun; 15(6):721-34. PubMed ID: 24618813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
    Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.
    Bu R; Uddin S; Bavi P; Hussain AR; Al-Dayel F; Ghourab S; Ahmed M; Al-Kuraya KS
    Lab Invest; 2011 Jan; 91(1):124-37. PubMed ID: 20661229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.
    Kenessey I; Keszthelyi M; Krámer Z; Berta J; Adám A; Dobos J; Mildner M; Flachner B; Cseh S; Barna G; Szokol B; Orfi L; Kéri G; Döme B; Klepetko W; Tímár J; Tóvári J
    Curr Cancer Drug Targets; 2010 May; 10(3):332-42. PubMed ID: 20370683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
    Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
    Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAGI3 Suppresses Glioma Cell Proliferation via Upregulation of PTEN Expression.
    Ma Q; Zhang Y; Meng R; Xie KM; Xiong Y; Lin S; He ZL; Tao T; Yang Y; Zhao JZ; He JQ
    Biomed Environ Sci; 2015 Jul; 28(7):502-9. PubMed ID: 26248734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
    Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
    Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
    Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
    Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.